Modern research on psychedelics is turning the “turn-on, tune-in, and drop-out” culture of the 1960’s upside down. What was once considered a recreational activity is now an evidence-based treatment for psychiatric disease. But how can psychedelics be widely used to alleviate human suffering through clinician-guided treatment of illnesses such as depression, PTSD, and addiction? Do mystical-type and insightful-type experiences associated with these substances improve overall well-being in patients and in healthy individuals? How can investors make psychedelic medicine accessible by financing academic research and for-profit companies and clinics? What is next for the 21st century renaissance of psychedelic medicine as it becomes an established treatment and wellness aid?
Other Resources / Information
- How psychedelics (e.g., psilocybin, MDMA, and ketamine) work in the human body.
- The therapeutic potential of psychedelics for the treatment of illnesses (e.g. depression, PTSD, addiction) and for improving overall wellness.
- What is the role of scientists, clinicians, guides, and investors in championing psychedelic research/therapy.
- John Krystal, o Professor of Translational Research & Professor of Psychiatry, Neuroscience, and Psychology; Chair, Dept of Psychiatry; Chief of Psychiatry, Yale-New Haven Hospital; Co-Director, Yale Center for Clinical Investigation, Yale University
- Roland Griffiths, Professor in the Neuropsychopharmacology of Consciousness, Professor of Psychiatry and Behavioral Sciences, and Director of the Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Johns Hopkins University School of Medicine
- Rosalind Watts, Clinical Director, Synthesis Institute
- Tim Ferriss, Entrepreneur, investor, and author, not applicable
Melanie Brickman Borchard, Director, Life Sciences, New York Academy Of Sciences
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.